1. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (18th August 2021) Authors: Westphal, D.; Garzarolli, M.; Sergon, M.; Horak, P.; Hutter, B.; Becker, J.C.; Wiegel, M.; Maczey, E.; Blum, S.; Grosche‐Schlee, S.; Rütten, A.; Ugurel, S.; Stenzinger, A.; Glimm, H.; Aust, D.; Baretton, G.; Beissert, S.; Fröhling, S.; Redler, S.; Surowy, H. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (1st December 2021) Authors: Westphal, D.; Garzarolli, M.; Sergon, M.; Horak, P.; Hutter, B.; Becker, J.C.; Wiegel, M.; Maczey, E.; Blum, S.; Grosche‐Schlee, S.; Rütten, A.; Ugurel, S.; Stenzinger, A.; Glimm, H.; Aust, D.; Baretton, G.; Beissert, S.; Fröhling, S.; Redler, S.; Surowy, H. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. (29th September 2016) Authors: Dieter, S. M.; Heining, C.; Agaimy, A.; Huebschmann, D.; Bonekamp, D.; Hutter, B.; Ehrenberg, K. R.; Fröhlich, M.; Schlesner, M.; Scholl, C.; Schlemmer, H.-P.; Wolf, S.; Mavratzas, A.; Jung, C. S.; Gröschel, S.; von Kalle, C.; Eils, R.; Brors, B.; Penzel, R.; Kriegsmann, M. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗